Advice

following a full submission

apremilast (Otezla®) is accepted for use within NHS Scotland.
 
Indication under review: for the treatment of moderate to severe chronic plaque psoriasis in adult patients who failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or psoralen and ultraviolet-A light (PUVA).
 
In two phase III, randomised, placebo-controlled studies in patients with moderate to severe plaque psoriasis, a significantly greater proportion of patients who received apremilast achieved at least 75% improvement in the Psoriasis Area and Severity Index (PASI) score at 16 weeks compared with those who received placebo.

Download detailed advice251KB (PDF)

Download

Medicine details

Medicine name:
apremilast (Otezla) plaque psoriasis
SMC ID:
1052/15
Indication:
for the treatment of moderate to severe chronic plaque psoriasis in adult patients who have failed to respond to or who have a contraindication to, or are intolerant to other systemic therapy including ciclosporin, methotrexate or pSoralen and ultraviolet A light (PUVA).
Pharmaceutical company
Celgene Ltd
BNF chapter
Musculoskeletal and joint diseases, Skin
Submission type
Full
Status
Accepted
Date advice published
08 June 2015